national coverage determination
CMS Finalizes Blood-Based Colon Cancer Screening NCD with Non-Coverage for Epi ProColon
The final decision includes some changes, most notably removing requirements for guideline inclusion, but retains its technical performance benchmarks.
Germany Grants National Reimbursement for Three Additional Breast Cancer Biomarker Tests
Myriad Genetics' EndoPredict, Agendia's MammaPrint (distributed in Germany by PathoNext), and Veracyte's Prosigna will now be covered by public insurance.
CMS to Cover FDA-Approved, -Cleared NGS Germline Tests for Breast, Ovarian Cancer Patients
The final national coverage decision stipulates that NGS germline tests for assessing hereditary breast and ovarian cancer risk must have FDA's blessing.
CMS Reopens National Coverage Determination for NGS Testing in Advanced Cancer
The government payor asked the public to specifically weigh in on the evidence supporting germline testing to assess treatment benefit for patients with hereditary cancer syndromes.
CMS to Revisit National Coverage Determination on NGS Tumor Testing
CMS had received significant stakeholder feedback that germline NGS testing is not the same as somatic testing, and that the NCD as written would negatively impact patients.